

Analytical method development and method validation for the Simultaneous Estimation of Lamivudine and Stavudine in tablet dosage form by RP-HPLC

SRIVANI MALLEPELLI¹, NARASIMHARAO R², JAJOW SWAPNA³

HITS COLLEGE OF PHARMACY, Bogaram(V), Keesara(M), Hyderabad (A.P)-501 301, India.

*Corresponding Author Email: srivani.pharmacy@ymail.com

PHARMACEUTICAL SCIENCES

RESEARCH ARTICLE

RECEIVED ON 09-11-2011

ACCEPTED ON 24-11-2011

ABSTRACT

A high-performance liquid chromatographic method was developed and validated for the simultaneous estimation of two antiretroviral drugs viz. Lamivudine and Stavudine that constitute one of the first line regimens in antiretroviral therapy. The different analytical performance parameters such as linearity, precision, accuracy, specificity, were determined according to International Conference on Harmonization ICH Q2B guidelines. Chromatography was carried out by isocratic technique on a reversed-phase BDS HYPERSIL C18 column with mobile phase comprising of 0.1M disodium hydrogen phosphate anhydrous buffer: methanol, adjusted to pH 5 with glacial acetic acid in the ratio of 50:50, v/v and the chromatographic condition was set at a flow rate of 1ml/min with the UV detector at 238 nm. The retention time Lamivudine and Stavudine was 4.8 and 5.7 minute, respectively. The linearity of the calibration curves for each analyte in the desired concentration range is good (r2 > 0.999) by RP-HPLC method. The method was accurate and precise with recoveries in the range of 98 and 102% for all the two drugs and relative standard deviation (R.S.D.) <1%. The proposed methods were highly sensitive, precise and accurate and hence it can be successfully applied for the simultaneous estimation of Lamivudine and Stavudine in tablet dosage form.

KEYWORDS: Lamivudine, Stavudine, reverse phase, high performance liquid chromatography, validation, simultaneous estimation

INTRODUCTION

Multi-drug therapy has become the standard treatment for acquired immunodeficiency syndrome (AIDS)¹. The situation is imposed by the need to delay the development of resistance by the human immunodeficiency virus (HIV), the causative virus of AIDS, to single anti-HIV drugs and to minimize potential dose dependent side effect². The current typical regimen for treating HIV infection is to use a combination of at least two drugs, a practice known as 'highly active antiretroviral therapy' (HAART)³.

Lamivudine is chemically known as (2*R*,5*S*)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5yl]-2(1*H*)-pyrimidinone⁴ and stavudine is chemically 2',3',didehydro-3'-deoxythymidine⁵. Lamivudine is a nucleoside analog having potent in-vitro and in-vivo inhibitory activity against HIV reverse transcriptase⁶. Lamivudine specifically refers to the (-) enantiomer of the *cis*-racemate.

Literature survey reveals several methods that have been used for the quantitative determination of the two drugs individually or in combination with other drugs in pharmaceutical dosage forms or in human performance plasma by high chromatography⁷⁻¹⁰, spectrophotometry¹¹, LC/MS/MS¹² etc. RP-HPLC method with solid phase extraction procedure has been reported for simultaneous determination of six nucleoside analog reverse transcriptase inhibitors and 13 HIV suppressing drugs¹⁴ of which 3TC and d4T are a part. Besides, simultaneous quantification of several antiretroviral agents including these two drugs has been reported by a solid-liquid extraction procedure using RP-HPLC system^{15,16}.

HPLC methods are useful in the determination of drugs in pharmaceutical formulations especially those containing more than one active components. Therefore, the aim of this work was to develop a relatively simple HPLC method for simultaneous quantification of 3TC and d4T in antiretroviral FDCs without the necessity of sample pre-treatment. This



paper describes the development and validation of reliable, simple, stable and economic reverse phase HPLC assay, using UV detection for the simultaneous determination of 3TC and d4T in FDC tablets. The method appears to be suitable for quality control in pharmaceutical industry due to its sensitivity, simplicity, selectivity and lack of excipients interference.

MATERIALS & METHODS

Chemicals and Reagents: All chemicals and reagents used were of HPLC grade. Methanol, disodium hydrogen phosphate anhydrous, glacial acetic acid and reference standards were obtained from CHANDRA LABS (Hyderabad, A.P, India). Stavex-40 L tablets containing 3TC-15 mg and d4T- 3mg were provided by Aurabindo Pharmaceuticals Ltd., Hyderabad.

Instruments: The instrument used for the study was a Shimadzu High Performance Liquid Chromatography equipped with UV-Visible detector.

Chromatographic Conditions:

Column: BDS HYPERSIL C18, 250×4.6mm, 5µ Mobile phase: 0.1M disodium hydrogen phosphate anhydrous buffer: methanol, adjusted to pH 5 with glacial acetic acid (50:50, v/v)

Flow rate : 1ml/min

Detection wavelength: 238nm

Pump mode : Isocratic

Run Time : 10 minutes

Retention Time : 4.8 and 5.7 minute

respectively

Injection Volume : 20µL

Preparation of Standard Solution: Accurately weighed about 15mg and 3mg of Lamivudine and

Stavudine working standards and transferred into a 100ml volumetric flask, added 60ml of diluents, and sonicated to dissolve. Cooled to room temperature and diluted to volume with diluent.

Preparation of Sample Solution: 20 tablets of Lamivudine and Stavudine were weighed and powdered in glass mortar. The powder equivalent to 50mg was transferred into a 100 ml volumetric flask, 70 ml of diluent was added to it and was shaken by mechanical stirrer and sonicated for about 30 minutes by shaking at intervals of five minutes each and was diluted up to the mark with diluent and allowed to stand until the residue settles before taking an aliquot for further dilution. 5 ml of upper clear solution was transferred to a 10 ml volumetric flask and diluted with diluent up to the mark and the solution was filtered through 0.45 μm filter before injecting into the HPLC system.

Procedure for Assay: $20~\mu l$ of the Standard, Sample and Blank preparations in duplicate were injected separately into the HPLC system and the peak responses for Lamivudine and Stavudine were measured. The quantities from the peak area in mg of Lamivudine and Stavudine were calculated per tablet taken.

RESULTS: The composition of the mobile phase for development of chromatographic method was optimized by using different solvent mixtures of varying polarity. The best results were obtained 0.1Mdisodium hydrogen phosphate using anhydrous buffer: methanol, adjusted to pH 5 with glacial acetic acid in the ratio 50:50, v/v. This mobile phase showed good resolution of Lamivudine (3TC) and Stavudine (d4T) peak. The wavelength of detection selected was 238 nm, as both the drugs showed optimum absorbance at this wavelength. By our proposed method the retention time of 3TC and d4T was about 4.8 and 5.7 minute, respectively and none of the impurities were interfering in its assay (Fig. 1 & 2).






Figure 1: A typical chromatogram of Lamivudine and stavudine standard




Figure 2: A typical chromatogram of Lamivudine and stavudine sample

Validation of the method: The developed method has been validated for the assay of 3TC and d4T as guidelines^{17,18} per ICH by using following parameters.

Specificity and Selectivity: Specificity and selectivity were studied for the examination of the presence of

interfering components. It was checked by subjecting the drug solution in different stress conditions like Acid, Base, Peroxide and the degradation was noted.



Acid Stress (0.1 M HCl)

Table 1: Specificity testing (Acid stress)

Conce	ntration	Time	Retention	RT of degraded	
(μg/m	I)	(hrs)	time(min)	product	
ЗТС	d4T		3TC d4T		
15	3	0	4.81 5.75	-	
		24	4.86 5.80	-	

Base Stress (0.1M NaOH)

Table 2: Specificity testing (Base stress)

Conce	oncentration Time		Retention	RT of degraded	
(μg/m	I)	(hrs)	time(min)	product	
ЗТС	d4T		3TC d4T		
15	3	0	4.81 5.75	-	
		24	4.92 5.89	-	

Peroxide stress (5% H₂O₂)

Table 3: Specificity testing (Peroxide stress)

Conce	ntration	Time	Retentio	on	RT of degraded	
(μg/m	1)	(hrs)	time(mi	in)	product	
3TC	d4T		3TC d	4T		
15	3	0	4.81 5	.75	-	
		24	4.87	5.82	-	

Linearity: Linearity was studied by preparing standard solutions of 3TC and d4T at different concentration levels (Fig. 3 & 4). The responses

were found linear in the range of 15-90 $\mu g/ml$ and 3-18 $\mu g/ml$ for 3TC and d4T, respectively.




Figure 3: Linearity curve of standard Lamivudine




Figure 4: Linearity curve of standard Stavudine

Accuracy:

Accuracy was performed in triplicate for various concentrations of Lamivudine and Stavudine equivalent to 40, 50 and 60 % of the standard amount was injected into the HPLC system per the

test procedure. The average % recovery of Lamivudine and Stavudine was calculated. **Table 4:** Results of Analysis of Formulation and Recovery Studies

Table 4: Results of Analysis of Formulation and Recovery Studies Accuracy 40%

LAMIVUDINE

STAVUDINE

Sl.n		Area	Amt	%Amt		Area	Amt	%Amt
0			recovery	recovery			Recovery	rocovory
1	Std	1397.28					Recovery	recovery
					Std	233.348		
2	Recovery 01	1392.57	39.86	99.66%				
					Recovery 01	234.234	40.15	100.38%
3	Recovery02	1408.49	40.32	100.8%				
	, , ,				Recovery 02	232.258	39.81	99.53%
4	Recovery03	1387.31	39.71	99.28%				
				3,0	Recovery 03	232.496	39.85	99.63%

 $_{
m age}$ 55.



Accuracy 50%

LAMIVUDINE

STAVUDINE

Std	1581.69	recovery	Recovery			Recovery	recovery
	1581.69						I
D				Std	264.50		
Recovery	1593.16	50.36	100.72%	Recovery	265.83	50.25	100.5%
01				01			
Recovery	1585.617	50.12	100.24%	Recovery	264.65	50.02	100.05%
02				02			
Recovery	1591.74	50.31	100.63%	Recovery	264.05	50.67	99.83%
03				03			
	01 Recovery 02 Recovery	01 Recovery 1585.617 02 Recovery 1591.74	01 Recovery 1585.617 50.12 02 Recovery 1591.74 50.31	01 Recovery 1585.617 50.12 100.24% 02 Recovery 1591.74 50.31 100.63%	01	01	01

Accuracy 60%

LAMIVUDINE

STAVUDINE

Sl.no		Area	Amt	%Amt		Area	Amt	%Amt
			recovery	Recovery			Recovery	recovery
1	Std	2026.36			Std	331.25		
2	Recovery	1998.16	59.16	98.6%	Recovery	334.04	60.5	100.84%
	01				01			
3	Recovery	2026.75	60.01	100.01%	Recovery	332.19	61.07	100.28%
	02				02			
4	Recovery	2009.26	59.49	99.15%	Recovery	333.13	60.7	100.56%
	03				03			

Precision:

A) Method Repeatability: Six sample solutions of the same concentration (50%) were prepared and injected into the HPLC system as per test procedure.






Table 5: Results from determination of precision of analysis of 3TC and d4T

LAMIVUDINE STAVUDINE

SI.no	Rt	Area	Sl.no	Rt	Area
1	4.888	1563.914	1	5.783	232.314
2	4.84	1543.855	2	5.787	232.443
3	4.89	1560.421	3	5.852	232.645
4	4.862	1550.717	4	5.812	231.611
5	4.81	1528.764	5	5.753	234.953
6	4.798	1541.009	6	5.75	233.284
Avg	4.848	1548.113	Avg	5.789	232.875
Std dev	0.038905	13.04546	Std dev	0.03835	1.152155
%RSD	0.802496	0.842668	%RSD	0.662401	0.494753

B) Intermediate Precision (Analyst to Analyst variability): Two analysts as per test method conducted the study. For Analyst-1 Method Repeatability and for Analyst-2 six sample solutions of the same concentration (50%) were prepared and injected into the HPLC system as per test procedure.

Table 6: Results from determination of precision of analysis of 3TC and d4T

LAMIVUDINE

Sl.no	Rt	Area
1	4.827	1605.185
2	4.821	1615.218
3	4.831	1609.503
4	4.828	1613.581
5	4.826	1610.821
6	4.795	1612.165
Avg	4.821	1611.079
Std dev	0.01333	3.51739
%RSD	0.27599	0.21832

STAVUDINE

Sl.no	Rt	Area
1	5.792	261.381
2	5.782	263.138
3	5.794	262.162
4	5.79	264.786
5	5.791	260.234
6	5.752	265.754
Avg	5.783	262.909
Std dev	0.01597	1.90254
%RSD	0.27616	0.72365



Robustness and Ruggedness: Robustness was done by small deliberate changes in the chromatographic conditions and retention time of 3TC and d4T was noted. The factors selected were flow rate and % methanol in the mobile phase. The results remained unaffected by small variations in these parameters. Ruggedness of the method was checked by using

IJPBS | Volume 1 | Issue 4 | OCT-DEC | 2011 | 551-559

different analysts and instruments. The relative standard deviation of the results obtained from different analysts and instruments was < 1.0%.

Validation parameter

The method was validated by using the following parameters as shown in **Table 7.**

Table 7: Validation parameter of HPLC method for Lamivudine and Stavudine

Validation	Lamivudine (3TC)	Stavudine (d4T)
Parameter		
Linearity Range (μg/ml)	15-90	3-18
Regression equation	Y= 21.612x+12.113	Y=18.343x+1.1252
Correlation Coefficient (r ²)	0.9988	0.9979
Accuracy	98.6-100.8	99.53-100.84
Precision		
Method Repeatability (RSD %)	0.842668-0.802496	0.494753-0.662401
Intermediate Precision (RSD %)	0.21832-0.27599	0.72365-0.27616

CONCLUSION: The proposed method is rapid, accurate and sensitive. It makes use of fewer amounts of solvents and change of set of conditions requires a short time. Many samples can be simultaneously and suitably analysed for the routine quality control analysis of 3TC and d4T in bulk and its tablet dosage forms. It does not suffer from any interference due to common excipients present in pharmaceutical preparation and can be conveniently adopted for quality control analysis.

REFERENCES

- 1. Clercq, E. D. New developments in anti-HIV chemotherapy. Biochimica Biophysica Acta, 2002, 1587, 258-275.
- 2. Beach, J. W. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism and adverse reactions. Clinical Therapeutics, 1998, 20, 2-25.
- Gallant, J. E. Initial therapy of HIV infection. Journal of Clinical Virology, 2002, 25, 317-333.

- Anonymous, Indian Pharmacopoeia 2007, fifth edition, Vol. II, The Indian Pharmacopoeia Commission, Ghaziabad. 2007; Page no: 1276.
- 5. Anonymous, Indian Pharmacopoeia 2007, fifth edition, Vol. III, The Indian Pharmacopoeia Commission, Ghaziabad. 2007; Page no: 1745-1746.
- 6. Gilman, A. G. Antiretroviral agents, in: J.G. Hardman, L. E. Limbird(Eds), The Pharmacological Basis of Therapeutics, McGraw Medical Publishing Division, New York, 2001, Page no: 1349.
- 7. Tarinas, A.; Tapanes, R. D.; Ferrer, G.; Perez, J. Validation of high performance liquid chromatography methods for determination of zidovudine, stavudine, lamivudine and indinavir in human plasma. Farmacia Hospitalaria, 2007, 31(4), 243-247.
- 8. Kapoor, N.; Khandavilli, S.; Panchagnula, R. Simultaneous determination of lamivudine and stavudine in antiretroviral fixed dose combinations by first derivative spectrophotometry and high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41(3), 761-765.
- 9. Kapoor, N.; Khandavilli, S.; Panchagnula, R. Simultaneous determination of lamivudine, stavudine and nevirapine in



oviral fixed dose combinations by high performance

- antiretroviral fixed dose combinations by high performance liquid chromatography. Analytica Chimica Acta, 2006, 570(1), 41-45.
- 10. Verweij-van Wissen C. P. W. G. M.; Aarnoutse, R. E.; Burger, D. M. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. Journal of Chromatography B., 2005, 816(1-2), 121-129.
- 11. Sankar, D. G.; Reddy, M. V. V. N.; Rajendrakumar, J. M.; Murthy, T. K. Indian Journal of Pharmaceutical Sciences, 2002, 64, 504-506.
- 12. Kenney, K. B.; Wring, S. A.; Carr, R. M.; Wells, G. N.; Dunn, J. A. Journal of Pharm Biomed Anal, 2000, 22, 967.

IJPBS | Volume 1 | Issue 4 | OCT-DEC | 2011 | 551-559

- 13. Rezk, N.; Tidwell, R.; Kashuba, A. Journal of Chromatography B, 2003, 791, 127-147.
- 14. Simon, V.; Thiam, M.; Lipford, L. Journal of Chromatography A, 2001, 913, 447-453.
- 15. Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Journal of Chromatography B, 2000, 744, 227-240.
- Notari, S.; Bocedi, A.; Ippolito, G.; Narciso, P.; Pucillo, L. P.; Tossini, G.; Donnorso, R. P.; Gasparrini, F.; Ascenzi, P. Journal of Chromatography B, 2006, 831, 258-266.
- 17. Anonymous, ICH Guidelines: Validation of Analytical Procedures: Methodology Q2(B), 2003.
- 18. Raman M Singh et al. / Journal of Pharmacy Research 2009, 2(10), 1598-1600.



* Corresponding Author SRIVANI MALLEPELLI¹

HITS COLLEGE OF PHARMACY, Bogaram(V), Keesara(M), Hyderabad (A.P)-501 301, India.

Page **559**